Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Big pharma to add $60bn in sales by 2024

This article was originally published in Scrip

Executive Summary

Big pharma companies are set to grow their revenues by a modest 1.3% a year over the next 10 years, and oncology will slip from the top spot as the most lucrative therapy area. So says a new report on the outlook for big pharma from Datamonitor Healthcare. It forecasts that the top 16 US/European big pharma companies will see prescription drug revenues grow by $60bn to reach $499bn in 2024.

Topics

Related Companies

UsernamePublicRestriction

Register

SC029238

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel